David MD - Erasca Chief Officer

Erasca Management Efficiency

The company has return on total asset (ROA) of (0.1914) % which means that it has lost $0.1914 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.389) %, meaning that it created substantial loss on money invested by shareholders. Erasca's management efficiency ratios could be used to measure how well Erasca manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. Net Tangible Assets is likely to gain to about 497.3 M in 2024, whereas Total Assets are likely to drop slightly above 350.2 M in 2024.

Similar Executives

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers. The company was incorporated in 2018 and is headquartered in San Diego, California. Erasca operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. Erasca Inc (ERAS) is traded on NASDAQ Exchange in USA. It is located in 3115 Merryfield Row, San Diego, CA, United States, 92121 and employs 126 people. Erasca is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Erasca Inc Leadership Team

Erasca Stock Performance Indicators

Additional Tools for Erasca Stock Analysis